Loading
A phase 3 trial of Zanubrutinib and Tislelizumab in advanced solid tumours, run by BeOne Medicines, active and no longer recruiting.
A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib is a phase 3 interventional study registered as NCT04170283 by BeOne Medicines, with 955 participants enrolled, started 2020-01-16 and due to reach its primary completion in 2026-12-31. Interventions recorded: Zanubrutinib and Tislelizumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares BeOne Medicines (formerly BeiGene), Tislelizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Zanubrutinib, BeOne Medicines (formerly BeiGene), Small-molecule kinase inhibitors and the tag pipeline.
Shares Tislelizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Zanubrutinib, BeOne Medicines (formerly BeiGene), Small-molecule kinase inhibitors and the tag pipeline.
Shares Zanubrutinib, Small-molecule kinase inhibitors and the tag pipeline.
Shares Zanubrutinib, BeOne Medicines (formerly BeiGene), Small-molecule kinase inhibitors and the tag pipeline.
Shares Tislelizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Tislelizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/